154 related articles for article (PubMed ID: 33992120)
1. LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer.
Feng LY; Huang YZ; Zhang W; Li L
J Ovarian Res; 2021 May; 14(1):67. PubMed ID: 33992120
[TBL] [Abstract][Full Text] [Related]
2. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.
Feng LY; Yan BB; Huang YZ; Li L
Clin Epigenetics; 2021 Jul; 13(1):141. PubMed ID: 34289901
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
4. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.
Strathdee G; Vass JK; Oien KA; Siddiqui N; Curto-Garcia J; Brown R
Gynecol Oncol; 2005 Jun; 97(3):898-903. PubMed ID: 15894365
[TBL] [Abstract][Full Text] [Related]
5. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer.
Sung HY; Yang SD; Park AK; Ju W; Ahn JH
Yonsei Med J; 2017 Jan; 58(1):27-34. PubMed ID: 27873492
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.
Yang C; Cai J; Wang Q; Tang H; Cao J; Wu L; Wang Z
Gynecol Oncol; 2012 Feb; 124(2):325-34. PubMed ID: 22005523
[TBL] [Abstract][Full Text] [Related]
9. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.
Wang N; Zhang H; Yao Q; Wang Y; Dai S; Yang X
J Exp Clin Cancer Res; 2012 Jan; 31(1):6. PubMed ID: 22248469
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer.
Lund RJ; Huhtinen K; Salmi J; Rantala J; Nguyen EV; Moulder R; Goodlett DR; Lahesmaa R; Carpén O
Sci Rep; 2017 May; 7(1):1469. PubMed ID: 28473707
[TBL] [Abstract][Full Text] [Related]
11. Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands.
Dai W; Teodoridis JM; Graham J; Zeller C; Huang TH; Yan P; Vass JK; Brown R; Paul J
BMC Bioinformatics; 2008 Aug; 9():337. PubMed ID: 18691414
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
13. Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.
Flanagan JM; Wilson A; Koo C; Masrour N; Gallon J; Loomis E; Flower K; Wilhelm-Benartzi C; Hergovich A; Cunnea P; Gabra H; Braicu EI; Sehouli J; Darb-Esfahani S; Vanderstichele A; Vergote I; Kreuzinger C; Castillo-Tong DC; Wisman GBA; Berns EM; Siddiqui N; Paul J; Brown R
Clin Cancer Res; 2017 May; 23(9):2213-2222. PubMed ID: 27663594
[No Abstract] [Full Text] [Related]
14. Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
Vaclavikova R; Klajic J; Brynychova V; Elsnerova K; Alnaes GIG; Tost J; Kristensen VN; Rob L; Kodet R; Skapa P; Mrhalova M; Soucek P
Oncol Rep; 2019 Aug; 42(2):763-774. PubMed ID: 31173253
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
16. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer.
Burton ER; Gaffar A; Lee SJ; Adeshuko F; Whitney KD; Chung JY; Hewitt SM; Huang GS; Goldberg GL; Libutti SK; Kwon M
Mol Cancer Res; 2011 Aug; 9(8):1126-38. PubMed ID: 21693594
[TBL] [Abstract][Full Text] [Related]
18. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
[TBL] [Abstract][Full Text] [Related]
19. [E-cadherin promoter methylation and demethylation in epithelial ovarian carcinoma cells].
Qu PP; Shi Z; Li N
Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):538-41. PubMed ID: 19957556
[TBL] [Abstract][Full Text] [Related]
20. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer.
Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J
Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
